Improved insulin sensitivity by anti-TNFα antibody treatment in patients with rheumatic diseases
FC Huvers, C Popa, MG Netea… - Annals of the …, 2007 - ard.bmj.com
FC Huvers, C Popa, MG Netea, FHJ van den Hoogen, CJ Tack
Annals of the rheumatic diseases, 2007•ard.bmj.com1 Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with
estrogen deprivation. Arthritis Rheum 2005; 52: 2594–8. 2 Coombes RC, Hall E, Gibson LJ,
Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three
years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J
Med 2004; 350: 1081–92.
estrogen deprivation. Arthritis Rheum 2005; 52: 2594–8. 2 Coombes RC, Hall E, Gibson LJ,
Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three
years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J
Med 2004; 350: 1081–92.
1 Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005; 52: 2594–8. 2 Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
ard.bmj.com